Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Atom Bioscience’s Novel Gout Therapy Meets Efficacy Endpoint

publication date: Mar 23, 2022

Jiangsu Atom Bioscience reported its treatment for gout met its primary efficacy endpoint in a double-blind placebo-controlled Phase IIa trial. ABP-671 is a small molecule inhibitor of the urate transporter protein that increases the excretion of uric acid to prevent gout attacks. Atom says ABP-671 reduced serum uric acid levels  to less than 6 mg/dL, below the clinically defined threshold of 7 mg/dL, without showing any serious safety concerns. Earlier this year, Atom Bio closed a $45 million Series C financing to support a global Phase III clinical trial of ABP-671. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here